Starbucks union plans Red Cup Day strike in 25+ cities - Bloomberg
Investing.com - Raymond James raised its price target on Abbvie (NYSE:ABBV) to $256.00 from $250.00 on Monday, maintaining an Outperform rating following the company’s third-quarter results. According to InvestingPro data, analysts have set targets ranging from $184 to $284, with the current consensus suggesting approximately 11% upside potential from current levels. The stock is currently trading near its Fair Value based on InvestingPro’s proprietary valuation model.
The pharmaceutical company delivered what Raymond James described as a "solid" quarter overall, beating expectations and raising guidance for the third time this year despite absorbing some macroeconomic headwinds. Abbvie’s revenue grew 7.4% over the last twelve months, reaching $59.64 billion, with a robust gross profit margin of 71.2%.
Abbvie’s strong fundamentals were led by key growth engines within its Immunology and Neuro divisions, with Skyrizi and the migraine franchise standing out as notable performers. The company’s diversification helped it absorb greater Humira erosion and continued challenges in its Aesthetics business. InvestingPro rates Abbvie’s overall financial health as "GOOD" with particularly strong scores in profitability metrics.
The stock experienced a 4.5% selloff on Friday, which Raymond James attributed to uncertainties regarding potential impacts from IRA price negotiations on several products in the coming years, including Imbruvica, Vraylar, and Linzess, as well as the repeatedly delayed rebound in Aesthetics. Despite this recent volatility, Abbvie generally trades with low price volatility, with a beta of just 0.51 over the past five years.
Despite these challenges, Abbvie reiterated its confidence in delivering high single-digit revenue growth through the end of the decade, emphasizing its expanding pipeline that positions the company to sustain strong growth into the next decade. InvestingPro data shows Abbvie has raised its dividend for 13 consecutive years, currently yielding 3.17%, and has delivered strong returns over both the past five and ten years. For investors seeking deeper insights, Abbvie is among the 1,400+ US stocks with comprehensive Pro Research Reports that transform complex data into actionable intelligence.
In other recent news, AbbVie Inc. reported its third-quarter 2025 earnings, which exceeded Wall Street expectations. The company posted an adjusted earnings per share (EPS) of $1.86, surpassing the forecasted $1.78. AbbVie also reported revenues of $15.8 billion, slightly higher than the anticipated $15.58 billion. Despite these positive earnings results, the company’s stock experienced a decline, reflecting broader market concerns and potential challenges within specific segments. These recent developments highlight the complexities facing AbbVie as it navigates market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.